In this episode, Ayesha spoke with Jonathan Rigby, MBA, CEO of Sernova, a Canadian biotech company developing innovative cell therapy-based approaches for the management of type 1 diabetes.

The company’s lead innovation is an implantable bio-hybrid organ pouch, which is currently in an ongoing Phase I/II clinical trial.

An estimated 537 million people are currently living with diabetes globally and this number is projected to reach 643 million by 2030, making it a pressing health issue in need of new, effective solutions.

Jonathan has held leaderships positions at several biopharmaceutical companies over his career. Prior to heading Sernova as its CEO, Jonathan served as President and CEO of Revolo Biotherapeutics where he took the company through multiple financings and two Phase II clinical trials. He also served as Chairman and Chief Business Officer of BIOS Acquisition Corporation, with an oversold IPO.

He also currently serves on the Board of Directors of cancer therapy company Oncolytics Biotech Inc. and IM Therapeutics, which is developing therapies for type 1 diabetes.

Tune into the episode to learn about Sernovo’s innovative cell-based approaches for the development of type 1 diabetes treatments.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Twitter: https://twitter.com/Xtalks